- Jubilant Pharmova - Jubilant Pharmova is a diversified pharmaceutical company built on a simple idea: own the niche where competition is scarce and barriers are high. It was created in 2021 when the Life Science Ingredients business was demerged from the company into Jubilant Ingrevia Limited and the company was renamed from Jubilant Life Sciences Limited to Jubilant Pharmova Limited, and it has since been reshaped around six specialty engines - from nuclear medicine and allergy shots to sterile injectable manufacturing and novel cancer drugs - that share a common thread of vertical integration, where in-house ingredients feed in-house factories and, in some cases, in-house distribution. The recurring approach is to find a corner of healthcare with regulatory or logistical moats, build an integrated ecosystem around it, and then deepen that moat with capacity investments that rivals find hard to replicate.
Business segments
Six engines at different stages - a radiopharma platform that makes and delivers time-sensitive nuclear medicines, a century-old allergy franchise, a sterile injectables factory doubling in size, a drug-discovery-to-API chain, a generics business rebuilding after regulatory setbacks, and a pre-revenue pipeline of novel precision drugs - each built on the cash flows and capabilities of the ones before.
1. Radiopharma: a nuclear medicine platform that makes the drug and owns the truck
It is the number-three manufacturer of radiopharmaceuticals in the US and runs the country's second-largest radiopharmacy network, delivering roughly 3 million patient doses a year to 1,800 hospitals - a model where manufacturing and last-mile distribution reinforce each other.
- The razor-blade model in cardiac imaging - its flagship product, Ruby-Fill®, is a Rubidium-82 generator used in PET scans for heart disease; once the elution system (the “razor”) is installed in a hospital, a fresh generator (the “blade”) is delivered every six to seven weeks, creating an annuity-like revenue stream. The generator lasts seven weeks versus the six-week industry standard, and its install base grew 35% in FY26.
- A monopoly in thyroid treatment - HICON®, its I-131 solution, has no direct competition in the US, making it a standard of care for hyperthyroidism and selected cases of thyroid carcinoma.
- A distribution network that doubles as a moat - 42 radiopharmacies across 21 states dispense six customised doses every minute with 99%-plus on-time delivery, using an owned fleet of roughly 400 vehicles and AI route optimisation. Because isotopes decay in hours or days, proximity to the customer is everything, and building a competing network requires navigating stringent Nuclear Regulatory Commission licences and state-level hospital regulations.
- A pipeline that expands the addressable market - the current portfolio addresses a USD 400 million market; seven new PET and SPECT imaging products are in development, targeting an incremental USD 535 million opportunity with launches planned between FY27 and FY29. A Phase II trial for I-131 MIBG, a treatment for the paediatric cancer neuroblastoma (roughly 400 relapsed cases a year in the US), completed dosing in April 2024, with a new drug application filing expected in the second half of FY27.
- A USD 50 million bet on PET manufacturing - the company is expanding from three to nine PET manufacturing sites by FY28, each requiring an investment of roughly USD 8 to 10 million and capable of delivering a one-time asset turn and returns on capital above 20%. Two sites have already begun distributing Pylarify®, a leading prostate cancer imaging agent, under contract manufacturing partnerships.
2. CDMO Sterile Injectables: the factory doubling in size while the industry runs short
It is a contract manufacturer of sterile injectable medicines for some of the world's largest pharmaceutical companies, operating from two North American facilities and in the middle of a capacity expansion that will shift its mix from mostly small-molecule drugs to mostly complex biologics.
- Long-duration contracts with the top tier - it serves five of the top 20 global pharma companies, with a 92% customer retention rate and an average relationship exceeding five years for its top ten customers. Most contracts run three-plus years with auto-renewal, and switching a product to another manufacturer takes roughly 24 months because of the technology transfer and regulatory effort involved.
- Two new high-speed lines, partly funded by the US government - Line 3 launched in October 2025 at the Spokane, Washington flagship, adding 50% more capacity with a USD 132 million investment; Line 4 is on track, and together they are expected to reach a combined peak revenue of USD 160 to 180 million. The US Department of Health and Human Services, through BARDA, is providing USD 149.6 million of the total USD 285 million expansion cost under a cooperative agreement, reflecting the government's interest in onshore sterile manufacturing capacity.
- Biologics are the future of the order book - roughly 80% of the products undergoing tech transfer onto Line 3 are complex biologics, which have tighter aseptic processing windows and higher switching costs than small-molecule drugs, so the company commands a price premium. One of the world's largest oncology products has already been onboarded onto Line 3.
- A second front in Montreal - a new isolator-based fill-finish line (Line 5) is under construction at the Canadian facility, backed by approximately US $40 million in funding from the Canadian government through partially repayable loans and other methods, with tech-transfer revenue expected from FY29. The same site is also adding a 200-bottle-per-minute ophthalmic filling line that would make it the first North American contract manufacturer to offer additive-free eye-care products.
3. CRDMO: the drug-discovery-to-factory chain
It combines India's leading integrated drug discovery service with an active pharmaceutical ingredient (API) manufacturing plant, offering global pharma and biotech companies a single chain from early-stage molecule design to commercial-scale production.
- A discovery engine with big-pharma validation - operating under Jubilant Biosys, the drug discovery business has delivered 85+ programs including Big pharma strategic partnerships and serves eight of the top 20 pharma companies, with revenue from large pharma rising from under 5% in FY23 to roughly a quarter in FY25. Three large pharmaceutical companies were onboarded as clients in FY25 alone.
- Three research centres, one French biologics outpost - roughly 400 scientists work at the Bengaluru integrated discovery centre, about 750 at the Delhi chemistry innovation hub, and a team of roughly 35 in St. Julien, France, covers the full antibody-drug conjugate (ADC) discovery loop after the company acquired an 80% stake in a Pierre Fabre R&D centre. The French addition expands the addressable market by USD 1.4 billion.
- Brought under one roof in 2025 - the API business was transferred from the listed parent into Jubilant Biosys in September 2025, creating an end-to-end CRDMO where a client can take a molecule from discovery through clinical trial supply to commercial manufacturing without changing partners.
4. Allergy Immunotherapy: the sole supplier of venom shots in America
It is the number-two player in the US subcutaneous allergy immunotherapy market and the only manufacturer of venom immunotherapy in the country, operating under the 100-year-old HollisterStier brand from a single FDA-approved facility in Spokane, Washington.
- A monopoly on insect-sting protection - after a competitor exited in 2018, the company became the sole supplier of venom immunotherapy in the US and Canada, with an efficacy rating of up to 98% in preventing systemic reactions to insect stings. It produces six venom products covering Honey Bee, Wasp, Yellow Jacket and other stinging insects.
- A portfolio of over 200 allergenic extracts - the range spans dog, cat, mite and tree pollen extracts, sold in bulk through a dedicated sales force to more than 2,000 allergists and physicians who administer immunotherapy in their clinics. The skin-testing devices use stainless steel lancets rather than plastic tips, a differentiation that minimises patient trauma.
- Grandfathered in, hard to displace - most existing allergy products hold grandfather status with regulators, while new products require biologic license approvals and a complete portfolio requiring significant investment and long development lead times. The raw-material supply chain - natural extracts and organisms - is complex to source and process, adding another barrier.
5. Generics: a global generics business rebuilding its US footing
It develops and sells solid-dose generic medicines across more than 50 countries, with a manufacturing base in India and a sales presence in the US, UK and Middle East, while building a branded generics business in India.
- A factory cleared for US exports again - the Roorkee, India facility was under an FDA import alert from July 2021 until a successful audit in February 2024 concluded with a Voluntary Action Indicated classification, after which US-bound shipments are expected to increase gradually. The plant makes tablets, capsules and powders using complex processes like multi-unit pellet systems and extended-release coatings.
- A filing cupboard of 101 US applications - the company has filed 101 Abbreviated New Drug Applications in the US, with 70 approvals received, alongside dossiers in Europe, the UK, Canada and other markets. It launched four new products in the US in FY26.
- A branded play in India and direct presence abroad - in India, it is building a branded generics business focused on dyslipidemia, hypertension, diabetes and obesity, with the cardiovascular division reaching breakeven in Q4 FY24. Subsidiaries in the UK and UAE are establishing direct on-ground sales channels, with the UK unit holding import approval for 23 products as of March 2025.
6. Proprietary Novel Drugs: a clinical-stage bet on precision cancer pills
It is a pre-revenue, clinical-stage biotechnology engine developing oral small-molecule drugs for difficult-to-treat cancers and autoimmune diseases, using a proprietary discovery platform and a pipeline led by two programs with FDA Orphan Drug Designation.
- A first-in-class CoREST inhibitor in Phase II - JBI-802, the lead asset, is being tested in patients with Essential Thrombocythemia, a blood cancer with roughly 150,000 patients in the US and no new FDA-approved drug in about 30 years. Early clinical data showed rapid, dose-dependent platelet normalisation, and the drug has also shown anti-tumour response in non-small cell lung cancer patients with STK11 mutations.
- A brain-penetrant PRMT5 inhibitor in Phase I - JBI-778 is in first-in-human trials at major Indian oncology centres for lung cancer with EGFR mutations, high-grade glioma, and head and neck cancer, and has also received FDA Orphan Drug Designation.
- A discovery engine validated by out-licensing deals - the TIBEO platform integrates structure-based design and computational algorithms to find drugs against targets that others consider undruggable. A previous EGFR program was out-licensed to Lengo Therapeutics, which was subsequently acquired by Blueprint Medicines for roughly USD 250 million in cash plus USD 215 million in milestone payments.
Group structure and partners
The listed Indian parent controls a global network of operating subsidiaries, each housing one of the six business engines, with the promoters holding just under half the equity.
- The entire pharmaceutical business sits under Jubilant Pharma Limited, Singapore, a wholly-owned subsidiary that in turn controls operating companies in the US, Canada, Europe and India.
- Key operating arms include Jubilant HollisterStier LLC (sterile injectables and allergy, Spokane), Jubilant DraxImage Inc. (radiopharma, Montreal), Jubilant Biosys Limited (drug discovery and CDMO, India and France), Jubilant Generics Limited (generics, Roorkee), and Jubilant Therapeutics Inc. (novel drugs, New Jersey).
- The company previously held a 25.8% stake in SOFIE Biosciences, a molecular theranostics firm with 14 US radiopharmacies; it sold the entire stake in June 2024 for roughly USD 142.9 million, crystallising a gain on an original USD 25 million investment made in 2020.
- Promoters held 47.7% as of March 2026, with foreign institutions at 15.9% and domestic institutions at 11.6%.